Key Takeaways NVO stock climbed 9.1% after reports of strong first-week U.S. prescriptions for oral Wegovy.Reported data covers retail only and excludes NovoCare, implying actual early oral Wegovy sales may be higher.The FDA delayed Eli Lilly's oral GLP-1 decision to April 10, giving NVO more time to strengthen its lead.Shares of Novo Nordisk (NVO) rose 9.1% on Friday after the company reportedly recorded strong early prescription trends just one week following the early-January U.S. launch of the oral vers ...